Ascendis Pharma A/S

NASDAQ (USD): Ascendis Pharma A/S (ASND)

Last Price

126.85

Today's Change

+2.57 (2.06%)

Day's Change

118.05 - 133.00

Trading Volume

1,085,487

Profile
ASND

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Jan Moller Mikkelsen Mr. Jan Moller Mikkelsen

Full Time Employees:  879 879

IPO Date:  2015-01-28 2015-01-28

CIK:  0001612042 0001612042

ISIN:  US04351P1012 US04351P1012

CUSIP:  04351P101 04351P101

Beta:  0.65 0.65

Last Dividend:  0.00 0.00

Dcf Diff:  222.94 222.94

Dcf:  -80.97 -80.97

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Address

Tuborg Boulevard 12,
Hellerup, 2900, DK

45 70 22 22 44

http://ascendispharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment